Enquire

Enrich your medicines pipeline

The research partner that creates innovative solutions, builds dynamic relationships and enriches your medicines pipeline across a range of human diseases

Our Services

Offerings

Research Phases

Therapeutic Areas

Target Classes

Approaches & Techniques

Case Studies

MAP4K4: Kinase inhibitors for cardioprotection following heart attacks

Domainex designed novel, potent, highly selective, small-molecule inhibitors of MAP4K4, with potential cardioprotective drug properties. View more

Tankyrase: Inhibitors for the treatment of solid tumours

Domainex employed its LeadBuilder virtual screening technology to identify tankyrase inhibitors from which pre-clinical development candidates emerged. View more

Der p 1: Protease Inhibitors for the treatment of asthma

Domainex collaborated with St George’s University London & the University of Manchester on a programme of drug discovery which led to the successfully nomination of a candidate drug. View more

TBK1/IKKε: Kinase inhibitors for the treatment of interferonopathies

Domainex identified a drug candidate DMXD-011, a first-in-class small-molecule orally bioavailable inhibitor of TBK1/IKKε View more

FLIPP-FADD: PPI inhibitors for the treatment of solid tumours

Domainex and Queen's University Belfast have discovered the world’s first inhibitors of FLIP-FADD and produced viable leads for drug candidate selection View more

Ras: PPI inhibitors for the treatment of cancer

Domainex used its extensive experience of fragment- & structure-based drug design to develop a lead molecule with strong binding to RAS, an oncology target. View more

G9a: Lysine Methyltransferase Inhibitors for the Treatment of Cancer

Starting from a LeadBuilder screen we identified novel potent inhibitors of G9a, which have potential to be developed as treatments for a range of solid tumours. View more

G9a: A fragment-based drug design (FBDD) programme to identify lysine methyltransferase inhibitors for the treatment of cancer

Domainex identified several highly efficient fragment hits and after one round of elaboration a 10-fold increase in affinity was achieved. View more

News

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

Synthesis in Review: Understanding the latest developments in synthetic chemistry from Strain-Release enabled Friedel-Crafts Spirocyclisation to the single step conversion of amides to enamides

One Nucleus Genesis

Events

Mar 27 8th RSC-BMCS Fragment-based Drug Discovery Meeting (Fragments 2022)

Sep 13 17th Drug Discovery Innovation Programme

Tweets

Tweets by Domainex_UK

Start your next project with Domainex

Contact one of our experts today